KTH Royal Institute of Technology

A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.

The study found eight potential protein biomarkers differentially expressed in elderly Alzheimer's disease patients, and researchers are planning an expanded study.

NEW YORK (GenomeWeb News) – A consortium of European research institutions and private partners will use €5.3 million ($7.4 million) in funding to develop a microfluidics-based lab-on-a-chip device to identify and measure the concentration of circulating tumor cells in blood, one of the partners,

Name: Peter Nilsson
Title: Platform Director, Affinity Proteomics, SciLifeLab, Stockholm

While many countries are cutting back on funding for life science research, Sweden is not one of them, as the Northern European country's Prime Minister Fredrik Reinfeldt this week confirmed that his government intends to invest $320 million in life sciences over the next four ye

As part of the deal, KTH will also serve as a reference site for Arrayjet, and the two organizations will work together on publications and technology development.

When most people think of the array market, they might think of the whole-genome genotyping chips sold by firms like Affymetrix and Illumina. But for providers of array slides, printers, and scanners, the market increasingly is in protein chips, and business is good.

BioSilta said that the use of EnBase Flo will increase the efficiency of the secondary screening process by allowing the KTH researchers to scale down from a shake-flask culture format to a 96-well microtiter plate format.

The university is using the company’s EnBase technology in its proteomics studies.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.